title: Review article: economic issues in Crohn's disease--assessing the effects of new treatments on health-related quality of life.
abstract: The advent of highly effective yet costly new treatments for Crohn's disease will force clinicians, patients, and society to make important choices regarding the allocation of resources. Pharmacoeconomic analyses can be useful in deciding whether new technologies are of good value in comparison to established treatment regimens. In Crohn's disease conventional cost-effectiveness analyses are of limited use because surgery, death, and disease-related complications occur relatively infrequently. Alternatively, cost-utility models relate the incremental cost of new treatments to improvements in health-related quality of life. These analyses require the collection of valid cost and utility inputs that have only recently become available. Ultimately, cost-utility models should allow decision makers to make sensible choices for patients and society. This article describes the techniques of pharmacoeconomic analysis and reviews existing data on the measurement of costs and quality-of-life outcomes in Crohn's disease.
authors.affiliation: University of Western Ontario, London, Ontario, Canada.
authors.forename: B G
authors.initials: BG
authors.lastname: Feagan
mesh_terms: D000465:Algorithms; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D003365:Costs and Cost Analysis; D003424:Crohn Disease / Q000145:classification / Q000188:drug therapy* / Q000191:economics*; D003661:Decision Support Techniques; D017850:Economics, Pharmaceutical; D005765:Gastrointestinal Agents / Q000627:therapeutic use; D006760:Hospitalization / Q000191:economics; D006801:Humans; D000069285:Infliximab; D011594:Psychometrics; D011788:Quality of Life; D012720:Severity of Illness Index; D011795:Surveys and Questionnaires
chemical_list: D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D000069285:Infliximab